Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 5/20 | 0.36 |
| ▸ | LAP3 | P28838 | 3/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28865310 | 0.92 | GABBR2 (0.39) | ANPEPLAP3ERAP1GABRR1GABBR2 | |
| SCHEMBL331939 | 0.89 | ANPEP (0.42) | ANPEPLAP3ERAP1GABRR1GABBR2 | |
| Propylene Glycol SCHEMBL5488189 | 0.87 | TDP1 (0.50) | ANPEPLAP3ERAP1GABRR1GABBR2 | |
| SCHEMBL28725320 | 0.86 | ANPEP (0.40) | ANPEPLAP3ERAP1GABRR1GABBR2 | |
| SCHEMBL28725325 | 0.86 | ANPEP (0.40) | ANPEPLAP3ERAP1GABRR1GABBR2 | |
| SCHEMBL31074941 | 0.86 | ANPEP (0.40) | ANPEPLAP3ERAP1GABRR1GABBR2 | |
| SCHEMBL29265277 | 0.86 | ANPEP (0.40) | ANPEPLAP3ERAP1GABRR1GABBR2 | |
| Bromide SCHEMBL28549578 | 0.86 | ANPEP (0.40) | ANPEPLAP3ERAP1GABRR1GABBR2 | |
| SCHEMBL2253835 | 0.86 | ANPEP (0.40) | ANPEPLAP3ERAP1GABRR1GABBR2 | |
| Hydrochloric Acid SCHEMBL28552052 | 0.86 | ANPEP (0.40) | ANPEPLAP3ERAP1GABRR1GABBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9068119-B2 | Method for producing mono-hydroxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ester of a carobxylic acid and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-06-30 | — | — | US | disclosed |
| US-8987490-B2 | Method for the production of monohydroxy-functionalized dialkylphosphinic acids, esters, and salts using ethylene oxide, and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-03-24 | — | — | US | disclosed |
| EP-2373668-B1 | METHOD FOR PRODUCING MONO-HYDROXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS USING A VINYL ESTER OF A CARBOXYLIC ACID AND THE USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2013-09-11 | — | — | EP | disclosed |
| US-20110281983-A1 | Method for the Production of Monohydroxy-Functionalized Dialkylphosphinic Acids, Esters, and Salts Using Ethylene Oxide, and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-11-17 | — | — | US | disclosed |
| EP-2379574-A1 | METHOD FOR THE PRODUCTION OF MONOHYDROXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS USING ETHYLENE OXIDE, AND USE THEREOF | Clariant International Ltd. (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2373668-A1 | METHOD FOR PRODUCING MONO-HYDROXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS USING A VINYL ESTER OF A CARBOXYLIC ACID AND THE USE THEREOF | Clariant International Ltd. (CH) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010069417-A1 | METHOD FOR THE PRODUCTION OF MONOHYDROXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS USING ETHYLENE OXIDE, AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010063343-A1 | METHOD FOR PRODUCING MONO-HYDROXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS USING A VINYL ESTER OF A CARBOXYLIC ACID AND THE USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-06-10 | — | — | WO | disclosed |
| EP-0778843-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996008503-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281983-A1 | Method for the Production of Monohydroxy-Functionalized Dialkylphosphinic Acids, Esters, and Salts Using Ethylene Oxide, and Use Thereof | ACSL3, ACSL1, HACL2 | ANPEP 2753/4885LAP3 1419/4885ERAP1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.